EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
IGC Pharma, Inc. (IGC) had EBIT Margin of -1517.80% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.19M |
|
$-1.82M |
|
$0.09M |
|
$0.10M |
|
$3.09M |
|
$-2.90M |
|
$1.08M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-1.82M |
|
$-2.90M |
|
$-2.78M |
|
90.46M |
|
90.46M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$2.00M |
|
$2.17M |
|
$7.74M |
|
$9.74M |
|
$1.51M |
|
$0.13M |
|
$0.14M |
|
$1.65M |
|
$8.09M |
|
$3.21M |
|
$8.09M |
|
91.96M |
|
| Cash Flow Statement Financials | |
$-3.50M |
|
$0.21M |
|
$3.96M |
|
$0.41M |
|
$1.10M |
|
$0.70M |
|
$1.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
0.02 |
|
0.02 |
|
51.83% |
|
-1517.80% |
|
|
EBIT Margin |
-1517.80% |
-- |
|
-953.40% |
|
-953.40% |
|
$-2.85M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
0.14 |
|
4.66 |
|
19.32 |
|
-22.50% |
|
-56.68% |
|
-18.69% |
|
-22.14% |
|
$0.09 |
|
$-0.03 |
|
$-0.04 |
|